DE | EN | ES
 
 

News and press releases from HAPILA

Authorities confirm cGMP status for HAPILA’s Estriol estrogen API manufacturing

[Translate to Englisch:] Molekularstruktur von Estriol

17.02.22 High-potency active ingredient specialist HAPILA GmbH (HAPILA) has received regulatory confirmation that its manufacturing facility for innovative estrogen agonist API Estriol complies with Good Manufacturing Practice...[more]


HAPILA and Transo-Pharm expand cooperation

1/12/2022 HAPILA GmbH and Transo-Pharm Handels-GmbH are determined to deepen their relationship and have therefore jointly decided to expand the production capacities at the HAPILA site in Gera, mainly to meet the increasing...[more]


Planning for new GMP production facilities

HAPILA is ramping up its production capacity with two new GMP plants now in its manufacturing pipeline. The concept design is almost complete and includes a 240 m2 area for new GMP production facilities with a capacity of up to...[more]


HAPILA extends production capacity

HAPILA GmbH (HAPILA) has extended its production capabilities by installation of another pilot plant. The new plant has already delivered first outputs of the innovative API BTZ043 used for tuberculosis (TB) treatment. These...[more]


Authorities extend CEP certification for HAPILA’s Estriol estrogen API

Recently the EDQM (European Directorate for the Quality of Medicines & Health Care, headquarters in Strasbourg) renewed the Certificate of suitability of Monographs of the European Pharmacopoeia (CEP) for the active...[more]


Anti Tuberculosis Agent BTZ-043 commences Clinical Phase II

Since mid-November TB patients have been treated for the first time with the new substance BTZ-043 in Cape Town, South Africa. The study is being conducted in the PanACEA consortium in collaboration with the TASK Applied Science...[more]


HAPILA showcases advanced API synthesis expertise at CPhI Worldwide Frankfurt

HAPILA GmbH will again be an innovative presence at the huge CPhI Worldwide pharmaceutical fair, showcasing its abilities to develop drug substances at every step of the value chain. We will be an exhibitor in the API zone of the...[more]


Displaying results 1 to 7 out of 28
<< First < Previous 1-7 8-14 15-21 22-28 Next > Last >>